Filing Details

Accession Number:
0000950170-25-072768
Form Type:
13G Filing
Publication Date:
2025-05-14 20:00:00
Filed By:
TCG Crossover GP II, LLC
Company:
Adverum Biotechnologies Inc. (NASDAQ:ADVM)
Filing Date:
2025-05-15
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
TCG Crossover GP II, LLC 0 1,871,482 8.9%
TCG Crossover Fund II, L.P. 0 1,871,482 8.9%
Chen Yu 0 1,871,482 8.9%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 1,796,482 shares of Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) and (ii) 75,000 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants (as defined and described in the Form 8-K filed with the Securities and Exchange Commission (the SEC) on February 5, 2024). The amount beneficially owned by each Reporting Person is determined based on 20,890,540 shares of Common Stock outstanding as reported in the Issuer's Form 10-K filed with the SEC on April 15, 2025 (the Form 10-K), plus 75,000 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


SCHEDULE 13G



Comment for Type of Reporting Person:  These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 1,796,482 shares of Common Stock and (ii) 75,000 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants. The amount beneficially owned by each Reporting Person is determined based on 20,890,540 shares of Common Stock outstanding as reported in the Issuer's Form 10-K, plus 75,000 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


SCHEDULE 13G



Comment for Type of Reporting Person:  These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 1,796,482 shares of Common Stock and (ii) 75,000 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants. The amount beneficially owned by each Reporting Person is determined based on 20,890,540 shares of Common Stock outstanding as reported in the Issuer's Form 10-K, plus 75,000 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


SCHEDULE 13G


 
TCG Crossover GP II, LLC
 
Signature:/s/ Craig Skaling
Name/Title:Authorized Signatory
Date:05/14/2025
 
TCG Crossover Fund II, L.P.
 
Signature:/s/ Craig Skaling
Name/Title:Authorized Signatory
Date:05/14/2025
 
Chen Yu
 
Signature:/s/ Craig Skaling
Name/Title:By POA as Attorney-in-Fact
Date:05/14/2025